Age- related macular degeneration with predominantly classic subfoveal choroidal neovascularisation MedDRA version: 8.1 Level: LLT Classification code 10015902 Term: Exudative senile macular degeneration of retina
Conditions
Interventions
Trade Name: Kenalog 40
Product Name: Kenalog 40
Pharmaceutical Form: Injection*
Sponsors
Department of Ophthalmology, Semmelweis University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged over 50 with CNV due to age-related macular degeneration with predominantly classic type of CNV at a subfoveal location (will be offered to participate in the study. Only patients otherwise amenable and willing to receive photodynamic therapy will be offered to participate in the trial. All patients must be willing to sign an informed consent and to return for follow-up visits up to one year. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: media opacities precluding biomicroscopy, fluorescein angiography (FA) or optical coherence tomography (OCT); CNV of any origin other than AMD, such as pathologic myopia, angioid streaks, choroidal rupture, presumed ocular histoplasmosis syndrome etc., other vascular disorders such as diabetic retinopathy more severe than „moderate” NPDR, and retinal vein occlusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The purpose of this study is to gather information on the safety and the synergist effect of intravitreal triamcinolone acetonide injections (IVTA), used in combination with Verteporfin photodynamic therapy.;Secondary Objective: ;Primary end point(s): • ratio of patients loosing less than 15 letters (3 lines) of visual acuity | — |
Countries
Hungary
Outcome results
None listed